WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) has taken bold steps to secure top talent by granting stock options and restricted stock units (RSUs) under its 2024 Inducement Plan. On January 2, 2025, the company announced awards of 215,000 stock options and 61,000 RSUs to a newly hired employee, aiming to align talent retention with the company’s growth objectives.
The grants, which comply with NASDAQ Listing Rule 5635(c)(4), are clear signals of Aclaris’ focus on attracting highly skilled professionals. The stock options carry an exercise price of $2.48, matching the company’s closing stock price on the grant date. Both the options and RSUs follow a four-year vesting schedule, with 25% of awards vesting on each anniversary of the grant, tied to continued employment.
This move reinforces Aclaris’ investment in innovation and its commitment to driving forward its mission in the competitive biotech landscape. By linking employee incentives to company performance, Aclaris sets the stage for long-term growth while strengthening its workforce.
With this strategic plan, Aclaris isn’t just hiring—it’s securing its future.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.